Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361998 | 1.00 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL1603859 | 0.86 | HSD17B10 (0.58) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL257244 | 0.85 | NR4A2 (0.51) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL29827082 | 0.85 | NR4A2 (0.51) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL1221627 | 0.85 | POLB (0.63) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL30362007 | 0.85 | POLB (0.63) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL2890368 | 0.84 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| Hydrochloric Acid SCHEMBL27134662 | 0.83 | POLB (0.61) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL1821903 | 0.83 | PTGDR2 (0.63) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 | |
| SCHEMBL17703257 | 0.83 | HSD17B10 (0.52) | ALDH1A1SMN1; SMN2MAPTHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268903-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250049765-A1 | BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-13 | — | — | US | disclosed |
| CN-118843613-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4448504-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448483-A1 | BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448500-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-6114175-A | AMYLOID-BINDING COMPOUNDS WHICH ARE NON-AZO DERIVATIVES OF CHRYSAMINE G TO DETERMINE DEGREE OF BRAIN DEPOSITS QUANTITATIVELY CHARACTERIZED BY AMYLOIDOSIS; DOWN'S SYNDROME; PREVENT CELL DEGENERATION; RADIOACTIVE IMAGING | UNIVERSITY OF PITTSBURGH (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0977815-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND $i(IN VIVO) IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-02-09 | — | — | EP | disclosed |
| CN-1226803-A | Diphenyl heterocycles as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 1999-08-25 | — | — | CN | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| WO-1998047969-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0823894-A1 | AZOCOMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-02-18 | — | — | EP | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996034853-A1 | AZOCOMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 1820/4885SMN1; SMN2 4221/4885MAPT 4739/4885 |
| US-20250268903-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 1820/4885SMN1; SMN2 4221/4885MAPT 4739/4885 |
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 1269/4885SMN1; SMN2 3618/4885MAPT 4733/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | ALDH1A1 828/4885SMN1; SMN2 4298/4885MAPT 2205/4885 |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 826/4885SMN1; SMN2 4394/4885MAPT 4598/4885 |
| US-20250049765-A1 | BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 2027/4885SMN1; SMN2 4469/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.